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ABSTRACT 
A young male schizophrenic presented with neuroleptic malignant syndrome (NMS). 
Risperidone was the probable precipitating agent. Rigidity and elevated CPK levels poorly responded 
to bromocriptine, but showed good response to dantrolene. The role of specific treatment and the 
differential response of the symptom clusters are discussed. 
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Neuroleptic malignant syndrome (NMS) 
is a rare, but potentially fatal and idiosyncratic 
reaction to neuroleptics (Delay & Deniker, 1968; 
Henderson & Wooten,1981; Morris etal, 1980). 
This syndrome consists of extra-pyramidal signs 
of rigidity and tremor; autonomic signs of 
hyperthermia, labile blood pressure, tachycardia, 
tachypnea, fever and diaphoresis, cognitive 
d
icturbances like confusion and altered 
sensorium; biochemical disturbances in the form 
of elevated creatine phosphokinase (CPK) 
(Delay & Deniker, 1968; Henderson & Wooten, 
1981). NMS has occurred mostly in patients 
receiving typical antipsychotics (Shalev et 
al.,1989). There are reports of NMS following 
atypical neuroleptics like risperidone, clozapine 
(Hasan & Buckley,1998) and olanzapine 
(Johnson & Bruxner.1998). We report a case of 
NMS involving risperidone and the usefulness 
of specific treatment, particularly bromocriptine 
and dantrolene. 
CASE REPORT 
Mr.A, a 22 year old male, is a case of 
paranoid schizophrenia (DSM-IV) of four year 
duration with positive as well as negative 
symptoms, and without any treatment. He was 
started on treatment with injection fluphenazine 
decanoate 25 mg i.m. fortnightly (suspected poor 
compliance) and chlorpromazine 400 mg PO/day. 
In view of prominent negative symptoms, severe 
EPS and no perceptible improvement with above 
drugs for four weeks, risperidone was started and 
was increased to 4 mg/day gradually. Six days 
after starting risperidone, the patient developed 
mild confusion and agitation. He left the hospital 
against medical advice. Three days later, the 
patient presented to the hospital with features of 
cognitive disturbances in the form of confusion 
and altered sensorium; autonomic instability in 
the form of profuse diaphoresis, tachycardia (100-
120 beats per min.), tachypnea (22-26 respirations 
per min), labile blood pressure (systolic varying 
between 130-150 mm Hg and diastolic varying 
between 90-100 mm Hg), fever (100 °F); 
neuromuscular disturbances in the form of 
generalized, extreme rigidity and tremors He was 
without any documented infection The CPK level 
at the time of admission was 4438U/L. His WBC 
count was 14,600 per cu. mm The results of 
cranial CT scan, chest X-ray, lumbar CSF 
analysis, metabolic profile and urine analysis were 
within normal limits. 
A diagnosis of NMS (Levenson,1985) 
was made. The antipsychotics were stopped and 
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supportive care was instituted There was 
improvement in his autonomic instability and CPK 
level decreased to 1908 U/L. Other clinical 
features continued to worsen The patient was 
started on bromocriptine on the fourth day. After 
36 hours of treatment with bromocriptine (7.5 mg/ 
day, PO) there was improvement in cognitive 
disturbances But, the rigidity remained the same 
and the CPK level rose upto 2957 U/L. So the 
patients was started on dantrolene which was 
gradually increased upto 200 mg/day at the rate 
of 50 mg every two days. Bromocriptine was 
increased upto 20 mg/day at the rate of 5 mg 
every two days Neuromuscular disturbances 
disappeared gradually over a period of 10 days 
and CPK level came down to 216 U/L. Dantrolene 
was tapered and stop over two days because of 
abnormal liver function tests (elevation of serum 
glutamate oxaloacetate transferase, serum 
glutamate pyruvate transferase, and alkaline 
phosphatase levels) after starting the drug. With 
the discontinuation of dantrolene, the rigidity re-
emerged and the CPK level rose from 216U/L 
to 918 U/L (Figure) As literature evidence favours 
dosage of bromocriptine upto 60 mg/day (Caroff 
&Mann, 1993), an attempt was made to increase 
bromocriptine It had to be aborted due to re-
emergence of symptoms like irritability and sleep 
disturbances The rigidity continued to worsen and 
the CPK level was increasing. Dantrolene was 
restarted after five days and all signs improved 
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Fig Effect of Dantrolene on serum CPK Although, there was 
an mstantial initial drop in serum CPK. it rose again while 
the patient was only on bromocriptine and began to fall only 
after treatment with Dantrolene Stopping this drug led to CPK 
elevation which again responded to Dantrolene treatment 
and CPK level dropped down to 213 U/L in next 
two days Repetition of liver function tests after 
restarting dantrolene did not show any 
abnormality. After ten days of patient being in a 
stable condition, bromocriptine and dantrolene 
were tapered and stopped. The patient recovered 
fully without any residual deficit. 
DISCUSSION 
Our patient was on typical neuroleptics 
for nearly one month before starting treatment 
with risperidone The manifestations on NMS in 
this case had been noticed within a week after 
starting risperidone. It has been observed that 
majority of patients (66%) who develop NMS do 
so within the first week of treatment with the 
offending agent (DSM-IV). It is likely, therefore, 
in this case risperidone was responsible in either 
causing or precipitating NMS. 
We suggest that the clinical features of 
NMS can be grouped into four clusters based on 
their response to treatment viz., autonomic 
disturbances, cognitive disturbances, 
neuromuscular disturbances and biochemical 
disturbances. Autonomic disturbances decreased 
with the stoppage of antipsychotics and supportive 
care. Cognitive disturbances were improved by 
treatment with bromocriptine. Neuromuscular 
disturbances and biochemical perturbations 
required dantrolene (Figure). Dantrolene is a 
skeletal muscle relaxant, which acts mostly 
through peripheral mechanism in improving the 
rigidity Two possible mechanisms have been 
implicated for rigidity in NMS First one, which 
postulates the central dopaminergic blockade, 
may not fully explain the rigidity in NMS, as 
bromocriptine, which is a dopamine agonist, was 
ineffective. Second mechanism is the peripheral 
one, which involves an impairment of the 
sarcoplasmic reticulum re-uptake of calcium in a 
genetically abnormal muscle as is proven in 
malignant hyperthermia (Bismuth et al. ,1984). Our 
case report supports the latter mechanism, since 
the rigidity continued to worsen when the patient 
was on bromocriptine alone and it promptly 
improved after the reinstitution of dantrolene. 
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In summary, risperidone can cause or 
precipitate NMS. There may be different clusters 
of symptoms, which may not respond to 
conservative treatment alone. Specific treatment 
like dantrolene may be necessary particularly 
for neuromuscular disturbances. 
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